stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Return on assets
Protagonist Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was 10.3%, up 28.8 percentage points from fiscal 2025 (−18.4%). Over the past ten years it has ranged from −118.1% (fiscal 2015) to 49.9% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −18.4% | (68.33) |
| FY2024 | 49.9% | 75.97 |
| FY2023 | −26.1% | 16.72 |
| FY2022 | −42.8% | (5.42) |
| FY2021 | −37.4% | (9.76) |
| FY2020 | −27.6% | 24.84 |
| FY2019 | −52.4% | (26.77) |
| FY2018 | −25.7% | 3.01 |
| FY2017 | −28.7% | 40.66 |
| FY2016 | −69.3% | 48.71 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| PTGX Protagonist Therapeutics, Inc. | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement